Aristeia Capital’s TriSalus Life Sciences TLSI Stock Holding History

Aristeia Capital’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,153,485	Closed	-$11.4M	–	739
2021 Q4	$11.4M	Hold	1,153,485	–	–	0.2%	133
2021 Q3	$11.5M	Hold	1,153,485	–	–	0.21%	137
2021 Q2	$11.2M	Hold	1,153,485	–	–	0.22%	142
2021 Q1	$11.1M	Buy	+1,153,485	New	+$11.7M	0.22%	149

Other funds holding TLSI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Aristeia Capital's TLSI Position: Q1 2022 in Review

Aristeia Capital sold out of TriSalus Life Sciences (TLSI) in Q1 2022, closing a stake of 1,153,485 shares — an estimated $11.4M sold.

Aristeia Capital first reported a position in TLSI in Q1 2021 and held it in 4 quarters. The position peaked at $11.5M in Q3 2021. 68 funds tracked by Wall St. Rank hold TLSI as of Q1 2022.

Aristeia Capital reported no remaining TriSalus Life Sciences position as of Q1 2022 after selling out during the quarter.
Aristeia Capital sold 1,153,485 TriSalus Life Sciences shares in Q1 2022, an estimated $11.4M.
Aristeia Capital first reported a position in TriSalus Life Sciences in Q1 2021 and held it in 4 quarters.
Aristeia Capital's TriSalus Life Sciences position peaked at $11.5M in Q3 2021.
68 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2022.

Based on Aristeia Capital's 13F filing for Q1 2022, filed 16 May 2022.